The use of GP IIb/IIIa inhibitors into new perspectives: pre-catheterization laboratory administration

No abstract is available for this paper.

• Publication year

  2005

• Venue

  European Heart Journal

• Publication date

  2005-10-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1093/EURHEARTJ/SUI062
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• Early eptifibatide improves TIMI 3 patency before primary percutaneous coronary intervention for acute ST elevation myocardial infarction: results of the randomized integrilin in acute myocardial infarction (INTAMI) pilot trial.

  2005cited by this paper
• Abciximab as adjunctive therapy to reperfusion in acute ST-segment elevation myocardial infarction: a meta-analysis of randomized trials.

  2005cited by this paper
• Early Administration of Reteplase Plus Abciximab vs Abciximab Alone in Patients With Acute Myocardial Infarction Referred for Percutaneous Coronary Intervention

  2004cited by this paper
• Short- and long-term recovery of left ventricular function predicted at the time of primary percutaneous coronary intervention in anterior myocardial infarction.

  2004cited by this paper
• Early vs late administration of glycoprotein IIb/IIIa inhibitors in primary percutaneous coronary intervention of acute ST-segment elevation myocardial infarction: a meta-analysis.

  2004cited by this paper
• Facilitated percutaneous coronary intervention versus primary percutaneous coronary intervention: design and rationale of the Facilitated Intervention with Enhanced Reperfusion Speed to Stop Events (FINESSE) trial.

  2004cited by this paper
• Facilitation of primary coronary angioplasty by early start of a glycoprotein 2b/3a inhibitor: results of the ongoing tirofiban in myocardial infarction evaluation (On-TIME) trial.

  2004cited by this paper
• Summary of recommendations on percutaneous coronary intervention for the reperfusion of acute ST elevation myocardial infarction

  2004cited by this paper
• Use of abciximab prior to primary angioplasty in STEMI results in early recanalization of the infarct-related artery and improved myocardial tissue reperfusion - results of the Austrian multi-centre randomized ReoPro-BRIDGING Study.

  2004cited by this paper
• P1502 Prehospital versus periprocedural administration of abciximab in STEMI: early and late results from the randomised REOMOBILE-study

  2003cited by this paper
• Intravenous glycoprotein IIb/IIIa receptor antagonists reduce mortality after percutaneous coronary interventions.

  2003cited by this paper
• Impact of Time to Treatment on Mortality After Prehospital Fibrinolysis or Primary Angioplasty: Data From the CAPTIM Randomized Clinical Trial

  2003cited by this paper
• Benefits and Risks of Abciximab Use in Primary Angioplasty for Acute Myocardial Infarction: The Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications (CADILLAC) Trial

  2003cited by this paper
• Primary angioplasty versus intravenous thrombolytic therapy for acute myocardial infarction: a quantitative review of 23 randomised trials.

  2003cited by this paper
• Myocardial viability, coronary flow reserve, and in-hospital predictors of late recovery of contractility following successful primary stenting for acute myocardial infarction

  2003cited by this paper
• Symptom-onset-to-balloon time and mortality in patients with acute myocardial infarction treated by primary angioplasty.

  2003cited by this paper
• A comparison of coronary angioplasty with fibrinolytic therapy in acute myocardial infarction.

  2003cited by this paper
• Transfer for Primary Angioplasty Versus Immediate Thrombolysis in Acute Myocardial Infarction: A Meta-Analysis

  2003cited by this paper
• Effect of tirofiban before primary angioplasty on initial coronary flow and early ST-segment resolution in patients with acute myocardial infarction.

  2003cited by this paper
• Adjunctive Platelet Glycoprotein IIb/IIIa Receptor Inhibition With Tirofiban Before Primary Angioplasty Improves Angiographic Outcomes: Results of the TIrofiban Given in the Emergency Room before Primary Angioplasty (TIGER-PA) Pilot Trial

  2003cited by this paper
• P2853 Early administration of abciximab bolus in the emergency room improves microperfusion after primary percutaneous coronary intervention, as assessed by TIMI Frame Count: results of the ERAMI trial

  2003cited by this paper
• Platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: a meta-analysis of all major randomised clinical trials.

  2002cited by this paper
• Primary angioplasty versus prehospital fibrinolysis in acute myocardial infarction: a randomised study.

  2002cited by this paper
• Effects of abciximab pretreatment in patients with acute myocardial infarction undergoing primary angioplasty.

  2002cited by this paper
• Relation of time to treatment and mortality in patients with acute myocardial infarction undergoing primary coronary angioplasty.

  2002cited by this paper
• Platelet glycoprotein IIb/IIIa inhibition with coronary stenting for acute myocardial infarction.

  2001cited by this paper
• Normal Flow (TIMI-3) Before Mechanical Reperfusion Therapy Is an Independent Determinant of Survival in Acute Myocardial Infarction: Analysis From the Primary Angioplasty in Myocardial Infarction Trials

  2001cited by this paper
• Importance of time to reperfusion on outcomes with primary coronary angioplasty for acute myocardial infarction (results from the Stent Primary Angioplasty in Myocardial Infarction Trial).

  2001cited by this paper
• Comparison of two platelet glycoprotein IIb/IIIa inhibitors, tirofiban and abciximab, for the prevention of ischemic events with percutaneous coronary revascularization.

  2001cited by this paper
• Meta-analysis of effectiveness and safety of abciximab versus eptifibatide or tirofiban in percutaneous coronary intervention.

  2001cited by this paper
• Relationship of symptom-onset-to-balloon time and door-to-balloon time with mortality in patients undergoing angioplasty for acute myocardial infarction.

  2000cited by this paper
• Multicentre randomized trial comparing transport to primary angioplasty vs immediate thrombolysis vs combined strategy for patients with acute myocardial infarction presenting to a community hospital without a catheterization laboratory. The PRAGUE study.

  2000cited by this paper
• A randomized trial comparing primary angioplasty with a strategy of short-acting thrombolysis and immediate planned rescue angioplasty in acute myocardial infarction: the PACT trial

  1999cited by this paper
• Relationship between delay in performing direct coronary angioplasty and early clinical outcome in patients with acute myocardial infarction: results from the global use of strategies to open occluded arteries in Acute Coronary Syndromes (GUSTO-IIb) trial.

  1999cited by this paper
• Effect of glycoprotein IIb/IIIa receptor blockade on recovery of coronary flow and left ventricular function after the placement of coronary-artery stents in acute myocardial infarction.

  1998cited by this paper
• Randomized, placebo-controlled trial of platelet glycoprotein IIb/IIIa blockade with primary angioplasty for acute myocardial infarction. ReoPro and Primary PTCA Organization and Randomized Trial (RAPPORT) Investigators.

  1998cited by this paper
• Selection of reperfusion therapy for individual patients with evolving myocardial infarction.

  1997cited by this paper
• Primary angioplasty in myocardial infarction.

  1995cited by this paper
• Thrombolysis and Myocardial Salvage Results of Clinical Trials and the Animal Paradigm‐ Paradoxic or Predictable?

  1993cited by this paper
• Activation of prothrombin accompanying thrombolysis with recombinant tissue-type plasminogen activator.

  1992cited by this paper
• A Prospective, Placebo‐Controlled, Randomized Trial of Intravenous Streptokinase and Angioplasty Versus Lone Angioplasty Therapy of Acute Myocardial Infarction

  1992cited by this paper
• Comparison of immediate invasive, delayed invasive, and conservative strategies after tissue-type plasminogen activator. Results of the Thrombolysis in Myocardial Infarction (TIMI) Phase II-A trial.

  1990cited by this paper
• A randomized trial of immediate versus delayed elective angioplasty after intravenous tissue plasminogen activator in acute myocardial infarction.

  1987cited by this paper
• The "wavefront phenomenon" of myocardial ischemic cell death. II. Transmural progression of necrosis within the framework of ischemic bed size (myocardium at risk) and collateral flow.

  1979cited by this paper

• Primäre PCI versus Thrombolyse

  2012influential citation
• Current Strategies and Future Trends

  2010cites this paper
• An organized system of emergency care for patients with myocardial infarction: a reality?

  2010cites this paper
• Antiplatelet intervention in acute coronary syndrome.

  2009influential citation
• Spontaneous recanalization of a completely occluded saphenous vein graft two months following acute myocardial infarction with persistent one year patency

  2009cites this paper
• GP IIb/IIIa inhibitors during primary percutaneous coronary intervention for STEMI: New trial and registry data

  2008cites this paper
• Antiplatelet therapy: current strategies and future trends.

  2006cites this paper
• Akutes Koronarsyndrom

  2006cites this paper
• Implementation of reperfusion therapy in acute myocardial infarction. A policy statement from the European Society of Cardiology.

  2005cites this paper